Consistency evaluation research and development cost list: 47 drugs over 10 million Hengrui Pharmaceuticals accounted for 9

Medicine Network June 5, as of 2020/6/2, according to incomplete statistics of the pharmaceutical Rubik's Cube, listed companies have announced the research and development costs of the adoption of consistent evaluation of drugs (including the same pass) a total of 156from the statistical results, research and development costs of less than 10 million yuan ofdrugs109, accounting for 70%, 10-20 million yuan of 34, accounting for 22%, more than 20 million have 13, accounting for 8%According to the registration classification, of the 20 drugs treated as a conformity evaluation, 13 had a cost greater than or greater than 10 million yuanhas now announced a consistent evaluation of research and development costs of drugs, Hengruipharmaceuticalacetate abitron (new 4 categories) research and development costs of the highest, up to 39.05 million yuanHengrui Pharmaceuticals is also the most consistent evaluation of research and development costs of more than 10 millionenterprises, a total of 9, followed by Huahai Pharmaceuticals, there are fourin terms of dosage forms, out of the 156 drugs that published consistent evaluation research and development costs, 5 have more than 10 million injectionsAmong the inhalers, Shenzhen's linoleic l-salbutamol inhalation solution (class 3) cost of research and development was the highest, at 2011.09 million yuantake zuo eracetan as an example, Jichuan Pharmaceutical's injection form research and development costs as high as 33.55 million, Jianmin Pharmaceutical's oral solution dosage form of 1982.09 million, Huahai Pharmaceutical's tablets (250mg, 500mg specifications) for 21.3 million, China Resources Seiko tablets (500mg specification) for 9.41 million